Background/Aim: We have reported that neonatal treatment with monosodium L-glutamate (MSG), which causes damage to the arcuate nucleus, leads to severe hyperleptinemia and reduced adrenal leptin receptor (ob-Rb) expression in adulthood. As a result, rats given MSG neonatally display corticoadrenal leptin-resistance, a defect that is overridden by normalization of corticoadrenal hyperfunction. The aim of the present study was to determine whether negative energy conditions could correct corticoadrenal cell dysfunction in rats given MSG neonatally. Methods: Normal (CTR) and MSG-treated female rats were subjected to food removal for 1–5 days, or prolonged (24–61 days) food restriction (FR). Plasma levels of several biomarkers and in vitro corticoadrenal function were evaluated following starvation or FR. Results: Fasting for 1–5 days reduced plasma leptin levels in CTR and MSG rats, compared to levels in the respective groups fed ad libitum(p < 0.05), but adrenal leptin-resistance was unchanged. With prolonged FR, isolated adrenal cells from MSG rats became sensitive to leptin, which lowered ACTH-induced glucocorticoid release. This restoration of leptin response was associated with normalization of adrenal ob-Rb gene expression. Conclusion: Dietary restriction in some leptin-resistant obese phenotypes may normalize adrenocortical function.

Keywords:
Leptin, Hypothalamo-pituitary-adrenal axis, ob-Rb gene expression, Food restriction
1.
Nemeroff CB, Grant LD, Bissette G, Erin GN, Harrell LE, Prange AJ: Growth, endocrinological and behavioral deficits after monosodium L-glutamate in the neonatal rat: possible involvement of arcuate dopamine neuron damage. Psychoneuroendocrinology 1977;2:179–196.
2.
Holzwarth-McBride MA, Sladek JR Jr, Knigge KM: Monosodium glutamate induced lesions of the arcuate nucleus. II. Fluorescence histochemistry of catecholamines. Anat Rec 1986;186:197–205.
3.
Krieger DT, Liotta AS, Nicholsen G, Kizer JS: Brain ACTH and endorphin reducedin rats with monosodium glutamate-induced arcuate nuclear lesions. Nature1979;278:562–563.
4.
Perello M, Gaillard RC, Chisari A, Spinedi E: Adrenal enucleation in MSG-damaged hyperleptinemic male rats transiently restores adrenal sensitivity to leptin. Neuroendocrinology 2003;78:176–184.
5.
Olney JW, Sharpe LG: Brain lesions in an infant rhesus monkey treated with monosodium glutamate. Science 1969;166:386–388.
6.
Burde RM, Schainker B, Kayes J: Acute effect of oral and subcutaneous administration of monosodium glutamate on the arcuate nucleus of the hypothalamus in mice and rats. Nature 1971;233:58–60.
7.
Badger TM, Millard WJ, Martin JB, Rosenblum PM, Levenson SE: Hypothalamic pituitary function in adult rats treated neonatally with monosodium glutamate. Endocrinology 1982;111:2031–2038.
8.
Larsen PJ, Mikkelsen JD, Jessop D, Lightman SL, Chowdrey HS: Neonatal monosodium glutamate treatment alters both the activity and the sensitivity of the rat hypothalamo-pituitary-adrenocortical axis. J Endocrinol 1994;141:497–503.
9.
Skultetyova I, Kiss A, Jezova D: Neurotoxic lesions induced by monosodium glutamate result in increased adenopituitary proopiomelanocortin gene expression and decreased corticosterone clearance in rats. Neuroendocrinology 1998;67:412–420.
10.
Macho L, Jezova D, Zorad S, Fickova M: Postnatal monosodium glutamate treatment results in attenuation of corticosterone metabolic rate in adult rats. Endocr Regul 1999;33:61–67.
11.
Dolnikoff MS, Kater CE, Egami M, de Andrade IS, Marmo MR: Neonatal treatment with monosodium glutamate increases plasma corticosterone in the rat. Neuroendocrinology 1988;48:645–649.
12.
Magarinos AM, Estivariz F, Morado MI, De Nicola AF: Regulation of the central nervous system-pituitary-adrenal axis in rats after neonatal treatment with monosodium glutamate. Neuroendocrinology 1988;48:105–111.
13.
Morris MJ, Tortelli CF, Filippis A, Proietto J: Reduced BAT function as a mechanism for obesity in the hypophagic, neuropeptide Y deficient monosodium glutamate-treated rat. Regul Pept 1998;75–76:441–447.
14.
Hirata AE, Andrade IS, Vaskevicius P, Dolnikoff MS: Monosodium glutamate (MSG)-obese rats develop glucose intolerance and insulin resistance to peripheral glucose uptake. Braz J Med Biol Res 1997;30:671–674.
15.
Bliss EL, Ailion J, Zwanziger J: Metabolism of norepinephrine, serotonin and dopamine in rat brain with stress. J Pharmacol Exp Ther 1968;164:122–134.
16.
Palkovits M, Brownstein M, Kizer JS, Saavedra JM, Kopin IJ: Effect of stress on serotonin concentration and tryptophan hydroxylase activity of brain nuclei. Neuroendocrinology 1976;22:298–304.
17.
Dawson R, Pelleymounter MA, Millard WJ, Liu S, Eppler B: Attenuation of leptin-mediated effects by monosodium glutamate-induced arcuate nucleus damage. Am J Physiol 1997;273:E202–E206.
18.
Hamann A, Matthaei S: Regulation of energy balance by leptin. Exp Clin Endocrinol Diabetes 1996;104:293–300.
19.
Pralong FP, Roduit R, Waeber G, Castillo E, Mosimann F, Thorens B, Gaillard RC: Leptin inhibits directly glucocorticoid secretion by normal human and rat adrenal gland. Endocrinology 1998;139:4264–4268.
20.
Perello M, Moreno G, Camihort G, Luna G, Console G, Gaillard RC, Spinedi E: Nature of changes in adrenocortical function in chronic hyperleptinemic female rats. Endocrine 2004;24:167–175.
21.
Moreno G, Perello M, Camihort G, Luna G, Console G, Gaillard RC, Spinedi E: Impact of transient correction of increased adrenocortical activity in hypothalamo-damaged, hyperadipose female rat. Int J Obesity 2006;30:73–82.
22.
Spinedi E, Johnston CA, Negro-Vilar A: Increased responsiveness of the hypothalamic-pituitary axis after neurotoxin-induced hypothalamic denervation. Endocrinology 1984;115:267–272.
23.
Giovambattista A, Chisari AN, Corro L, Gaillard RC, Spinedi E: Metabolic, neuroendocrine and immune functions in basal conditions and during the acute-phase response to endotoxic shock in undernourished rats. Neuroimmunomodulation 2000;7:92–98.
24.
Giovambattista A, Chisari AN, Gaillard RC, Spinedi E: Food intake-induced leptin secretion modulates hypothalamo-pituitary-adrenal axis response and hypothalamic Ob-Rb expression to insulin administration. Neuroendocrinology 2000;72:341–349.
25.
Chisari A, Spinedi E, Voirol M-J, Giovambattista A, Gaillard RC: A phospholipase A2-related snake venom (from Crotalus durissus terrificus) stimulates neuroendocrine and immune functions: determination of different sites of action. Endocrinology 1998;139:617–625.
26.
Spinedi E, Giacomini M, Jacquier MC, Gaillard RC: Changes in the hypothalamocorticotrope axis after bilateral adrenalectomy: evidence for a median eminence site of glucocorticoid action. Neuroendocrinology 1991;53:160–170.
27.
Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156–159.
28.
Zar JH: Biostatistical Analysis. Englewood Cliffs. Prentice-Hall, 1974.
29.
Banks WA, Farr SA, Morley JE: The effects of high fat diets on the blood-brain barrier transport of leptin: failure or adaptation? Physiol Behav 2006;88:244–248.
30.
Dallman MF, Akana SF, Bhatnagar S, Bell ME, Choi S, Chu A, Horsley C, Levin N, Meijer O, Soriano LR, Strack AM, Viau V: Starvation: early signals, sensors, and sequelae. Endocrinology 1999;140:4015–4023.
31.
Ribeiro EB, do Nascimento CM, Andrade IS, Hirata AE, Dolnikoff MS: Hormonal and metabolic adaptations to fasting in monosodium glutamate-obese rats. J Comp Physiol 1997;167:430–437.
32.
Young JB, Landsberg L: Suppression of sympathetic nervous system during fasting. Science 1977;196:1473–1475.
33.
Nakagawa T, Ukai K, Ohyama T, Gomita Y, Okamura H: Effects of chronic administration of sibutramine on body weight, food intake and motor activity in neonatally monosodium glutamate-treated obese female rats: relationship of antiobesity effect with monoamines. Exp Anim 2000;49:239–249.
34.
Leigh FS, Kaufman LN, Young JB: Diminished epinephrine excretion in genetically obese (ob/ob) mice and monosodium glutamate-treated rats. Int J Obes Relat Metab Disord 1992;16:597–604.
35.
Perello M, Moreno G, Gaillard RC, Spinedi E: Glucocorticoid-dependency of increased adiposity in a model of hypothalamic obesity. Neuro-Endocrinol Lett 2004;25:119–126.
36.
Castrogiovanni D, Gaillard RC, Giovambattista A, Spinedi E: Neuroendocrine, metabolic, and immune functions during the acute phase response of inflammatory stress in monosodium L-glutamate-damaged, hyperadipose male rat. Neuroendocrinology 2008;88:227–234.
37.
Leitner C, Bartness TJ: Food deprivation-induced changes in body fat mobilization after neonatal monosodium glutamate treatment. Am J Physiol Regul Integr Comp Physiol 2008;294:R775–R783.
38.
Vidal-Puig AJ, Considine RV, Jimenez-Linan M, Werman A, Pories WJ, Caro JF, Flier JS: Peroxisome proliferator-activated receptor gene expression in human tissues: effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 1997;99:2416–2422.
39.
Shi XM, Blair HC, Yang X, McDonald JM, Cao X: Tandem repeat of C/EBP binding sites mediates PPARgamma2 gene transcription in glucocorticoid-induced adipocyte differentiation. J Cell Biochem 2000;76:518–527.
40.
Mueller E, Drori S, Aiyer A, Yie J, Sarraf P, Chen H, Hauser S, Rosen ED, Ge K, Roeder RG, Spiegelman BM: Genetic analysis of adipogenesis through peroxisome proliferator-activated receptor gamma isoforms. J Biol Chem 2002;277:41925–41930.
41.
El-Chaar D, Gagnon A, Sorisky A: Inhibition of insulin signaling and adipogenesis by rapamycin: effect on phosphorylation of p70 S6 kinase vs eIF4E-BP1. Int J Obes Relat Metab Disord 2004;28:191–198.
42.
Jacobson L, Zurakowski D, Majzoub JA: Protein malnutrition increases plasma adrenocorticotropin and anterior pituitary proopiomelanocortin messenger ribonucleic acid in the rat. Endocrinology 1997;138:1048–1057.
43.
Couillard C, Mauriege P, Imbeault P, Prud’homme D, Nadeau A, Tremblay A, Bouchard C, Despres JP: Hyperleptinemia is more closely associated with adipose cell hypertrophy than with adipose tissue hyperplasia. Int J Obes Relat Metab Disord 2000;24:782–788.
44.
Bailey JW, Barker RL, Beauchene RE: Age-related changes in rat adipose tissue cellularity are altered by dietary restriction and exercise. J Nutr 1993;123:52–58.
45.
Ahima RS, Flier JS: Leptin. Annu Rev Physiol 2000;62:413–437.
46.
Wang Z, Zhou YT, Kakuma T, Lee Y, Kalra SP, Kalra PS, Pan W, Unger RH: Leptin resistance of adipocytes in obesity: role of suppressors of cytokine signaling. Biochem Biophys Res Commun 2000;277:20–26.
47.
Li H, Matheny M, Nicolson M, Tumer N, Scarpace PJ: Leptin gene expression increases with age independent of increasing adiposity in rats. Diabetes 1997;46:2035–2039.
48.
Fernandez-Galaz C, Fernandez-Agullo T, Perez C, Peralta S, Arribas C, Andres A, Carrascosa JM, Ros M: Long-term food restriction prevents ageing-associated central leptin resistance in Wistar rats. Diabetologia 2002;45:997–1003.
49.
Perez C, Fernandez-Galaz C, Fernandez-Agullo T, Arribas C, Andres A, Ros M, Carrascosa JM: Leptin impairs insulin signaling in rat adipocytes. Diabetes 2004;53:347–353.
50.
Trayhurn P, Beattie JH: Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc 2001;60:329–339.
51.
Bluher S, Mantzoros CS: Leptin in reproduction. Curr Opin Endocrinol Diabetes Obes 2007;14:458–464.
52.
Lago F, Dieguez C, Gomez-Reino J, Gualillo O: Adipokines as emerging mediators of immune response and inflammation. Nat Clin Pract Rheumatol 2007;3:716–724.
53.
Walder K, Filippis A, Clark S, Zimmet P, Collier GR: Leptin inhibits insulin binding in isolated rat adipocytes. J Endocrinol 1997;155:R5–R7.
54.
DeVries AC, Joh HD, Bernard O, Hattori K, Hurn PD, Traystman RJ, Alkayed NJ: Social stress exacerbates stroke outcome by suppressing Bcl-2 expression. Proc Natl Acad Sci USA 2001;98:11824–11828.
55.
Holsboer F, Barden N: Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocr Rev 1996;17:187–205.
56.
Joels M: Corticosteroid actions in the hippocampus. J Neuroendocrinol 2001;13:657–669.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.